Accretion Nutraveda (544694)

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROCE of 56.66% suggests efficient capital employment, if sustainable.
• Latest quarter is profitable: ₹14 Cr sales with ₹2 Cr net profit, implying a net margin of about 14%.
• Market cap of ₹145 Cr is small, so even modest absolute profit improvements could matter.
• Positive net profit in the latest quarter provides some earnings base, despite zero historical growth.

Concerns

• P/E of 55.48 is dangerously high for a company with 0.00% sales and profit growth.
• Piotroski F-score of 3/9 indicates weak fundamental health and possible deterioration.
• Dividend yield is 0.00%, so there is no income cushion for shareholders.
• Critical data is missing: book value, ROE, debt/equity, promoter holding, and 52-week range, making valuation unreliable.

AI Analysis

At ₹200, Accretion Nutraveda carries a market capitalisation of ₹145 crore and a P/E of 55.48. That multiple implies trailing earnings of roughly ₹2.6 crore. For that price, the market is paying for future growth, yet the disclosed figures show sales growth of 0.00% and profit growth of 0.00%. As Graham taught, price is what you pay; value is what you get. I see very little value here. The latest quarter shows sales of ₹14 crore and net profit of ₹2 crore, giving a healthy net margin of about 14%, and ROCE of 56.66% catches the eye. But a high return on capital, with zero growth and a Piotroski F-score of only 3/9, is a warning sign. The F-score tells me the underlying fundamentals are weak and may even be deteriorating. I also do not have book value, ROE, debt/equity, or promoter holding. For a small pharmaceutical company, the absence of these basic checks is itself a red flag. There is no dividend, so any return must come from capital appreciation. At 55 times earnings, I need a durable moat and a long runway of compounding. I do not see that evidence. This is a slow grower priced like a fast grower, and the margin of safety is absent. In pharmaceuticals, product strength and distribution matter; none of that is visible from these numbers. I would put this in the too-hard pile. Indian retail investors should wait for higher F-score, consistent growth, and a much lower valuation before considering it.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer